RxDoctor Payments Data

Alberto Comas Espinal, MD

General Practice · New York, NYNPI 1679502785

Payments from drug & device makers

$1,409in general payments, 2019–2025

Across 79 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$382
  • E.r. Squibb & Sons, L.L.C.$290
  • GSK$251
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$136
  • Merck$60
  • Novartis$58
  • plus $232 from 9 others

What the payments were for

  • Food & beverage$1,409100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,409 in reported general payments places this provider in the 85th percentile of 5,764 general practice providers in New York.

See all general practice providers in New York

Medicare billing

Part B allowed, 2024
$21,878
Medicare patients
46
Services billed
301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide170$167,706
JanuviaSitagliptin Phosphate161$158,450
VascepaIcosapent Ethyl273$111,866
JanumetSitagliptin Phos/Metformin Hcl98$105,857
FarxigaDapagliflozin Propanediol107$98,046
JardianceEmpagliflozin91$95,126
Doxepin Hcl111$65,061
TrulicityDulaglutide50$62,253
Chlorpromazine Hcl79$60,351
LinzessLinaclotide53$46,238
BiktarvyBictegrav/Emtricit/Tenofov Ala11$44,020
EliquisApixaban45$38,715
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog131$35,533
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$29,729
Fluocinonide64$23,757

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet, Janumet Xr$60$278,458271 claims
AstraZenecaFarxiga, Symbicort, Nexium$17$120,046198 claims
Lilly USA, LLCTrulicity$47$62,25350 claims
AbbVieLinzess, Restasis$27$56,05369 claims
GSKTrelegy Ellipta, Breo Ellipta$251$49,16993 claims
PfizerEliquis$14$38,71545 claims
BayerKerendia$21$17,03318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,764 general practice providers in New York.

Other general practice in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →